Congress moves to unblock generic drugs stuck in FDA limbo
H.R. 1051 — To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes. · Filed by Nicole (Nikki) Budzinski (D-IL) · Introduced Feb 6, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends drug approval law to allow a second generic drug maker to get FDA approval if the first applicant fails to bring their drug to market within 33 months of filing. The second applicant must certify they can start selling within 75 days of approval; if they do, they get a 180-day head start before any other generics can enter. If the second applicant also fails to market within 75 days, they lose their approval and the process can repeat.
Why we flagged it
The bill's core mechanism is to unblock generic drug approvals when first applicants fail to commercialize, thereby accelerating patient access to lower-cost medications. This is a pro-competition, pro-access measure within pharmaceutical regulation.
What the text implies
- The 33-month waiting period may incentivize first applicants to file and immediately begin marketing even if demand is uncertain, potentially flooding the market with drugs that lack commercial viability.
- Second applicants must certify they can market within 75 days or lose approval; this creates a high bar that may exclude smaller generic manufacturers without rapid distribution infrastructure.
The full analysis lists 4 implications of this text.
Who stands to gain
generic pharmaceutical manufacturers; patients and insurers (via lower drug costs); pharmacy benefit managers